Dosage for TB-500: Research Ranges, Routes, and Cycles

There's no FDA-approved dose for TB-500. That's the honest starting point, and any guide that skips it is already misleading you.

What does exist is a body of animal research, almost all of it in rodents, plus a single published human pharmacokinetic study that used a different molecule (full-length Thymosin Beta-4, not the TB-500 fragment). Every dose number you'll see floating around the research community is extrapolated from that data using established interspecies scaling, then adjusted for the delivery route in play.

This guide covers the research-extrapolated range, route-by-route dose math, reconstitution for injectable protocols, and the cycle structure most researchers default to. All content is published for research purposes only. For the actin-binding mechanism and the broader picture of what TB-500 actually does, see the TB-500 fragment explainer.

What's the standard dosage for TB-500?

The figure most researchers anchor on is roughly 5 to 10 mg of TB-500 per week, split across two subcutaneous injections.

That's an extrapolation, not a validated clinical dose. It's derived from rodent studies that typically use 100 to 500 mcg per administration in animals weighing a few hundred grams, then scaled up using the FDA's published body-surface-area conversion. Some researchers run lower (around 2.5 mg per week for maintenance windows), some run higher (up to about 20 mg per week during loading), but the 5 to 10 mg weekly range is what most published protocols and community sources converge on.

Range	Weekly Dose	Typical Research Context
Maintenance	2 to 5 mg per week	Lower-intensity research windows; post-loading periods
Standard	5 to 10 mg per week	Active tissue repair research; first loading cycle
Intensive	10 to 20 mg per week	Short loading window in acute injury research

Three things to keep in mind before you treat any of these numbers as authoritative:

• No human trial validates them. They are translations from rodent data, not measurements in people.
• The route changes the effective dose. A capsule, a sublingual lozenge, and a subcutaneous injection at the same number on the label deliver very different amounts to your bloodstream.
• Weekly totals matter more than per-dose precision. Most protocols split the weekly dose into two administrations, three or four days apart.

How was the standard TB-500 dose actually derived?

Almost every TB-500 dose figure you'll read starts in a rat. Researchers then run two translations to get to a number for an adult human.

Step one is the FDA's interspecies scaling guidance, called Human Equivalent Dose (HED). It uses body surface area, not body weight, to convert between species. For rats, you divide the rat mg/kg dose by about 6.2 to get the human mg/kg HED. That's the standard published in the FDA's 2005 starting-dose guidance, still the working reference for first-in-human scaling.

How researchers scale a rat dose to a human dose using body surface area and weekly frequency.

Step two is where the maths gets messy: rodent studies don't use a single dose, they use a range, and researchers usually pick the upper end.

Run the numbers for an 80 kg adult using a typical rodent dose of 400 mcg per kg of rat body weight:

1. Rat dose: 400 mcg/kg in rat
2. HED conversion: 400 mcg/kg ÷ 6.2 = roughly 65 mcg/kg in human
3. Scaled to 80 kg adult: 65 mcg/kg × 80 kg = roughly 5.2 mg per administration
4. Twice-weekly schedule: 5.2 mg × 2 = roughly 10 mg per week

That's where the 5 to 10 mg per week range comes from. It is not a clinical recommendation; it is a body-surface-area translation from a single dose-finding curve in animals to a hypothetical human.

For researchers wanting the original source on this conversion methodology, the FDA's 2005 HED guidance walks through the rationale and the conversion factor table. Every credible peptide dose calculation uses the same starting point.

Does the TB-500 dose change based on how you take it?

Yes, and it's the single biggest variable in TB-500 dosing that most guides ignore.

Think of your bloodstream as the destination. Subcutaneous injection, sublingual absorption, and oral capsules are three different roads to get there, and each road has different checkpoints. The same number on three different labels delivers three different amounts of TB-500 to systemic circulation.

How TB-500 reaches your bloodstream differently depending on injection, sublingual, or oral delivery.

The route question matters most for TB-500 specifically because the peptide is large enough (seven amino acids) to be vulnerable to stomach acid and intestinal enzymes. A general-purpose primer on this is the oral vs injectable peptide bioavailability comparison.

Subcutaneous injection

Standard TB-500 subcutaneous dose: 2 to 5 mg per administration, two doses per week.

Subcutaneous injection (into the fat layer just under the skin) is the reference standard in TB-500 animal research. Practically all the rodent wound-healing and tissue-repair data uses this route. Bioavailability is effectively complete: the full dose enters circulation with minimal loss.

The twice-weekly schedule comes from TB-500's relatively slow systemic clearance compared to shorter peptides. Three or four days between doses is the default rhythm in most research protocols.

Sublingual delivery

Standard TB-500 sublingual dose: matches the injection dose when the delivery system has been validated for peptide bioavailability.

Sublingual absorption (dissolving a compound under your tongue) lets a peptide bypass the digestive system entirely. The underside of your tongue is densely lined with capillaries and a permeable mucosal membrane, so a molecule that's properly formulated can pass directly into your bloodstream without going anywhere near your stomach.

The key qualifier: bioavailability depends entirely on the delivery system being designed for peptides. A generic sublingual spray or a peptide simply placed under the tongue without a validated carrier doesn't match injection-level absorption. VERISORB Quicksome is one of the systems specifically engineered for sublingual peptide delivery, with bioavailability research suggests is comparable to subcutaneous administration.

When the delivery system is validated, the dose equivalence is direct: a 2 to 5 mg sublingual dose delivers a similar amount to circulation as a 2 to 5 mg subcutaneous injection. Practical mechanics matter here: hold the dose under your tongue for 60 to 90 seconds, ideally in a fasted state.

Standard oral capsules

Standard oral TB-500 dose: not a recommended route.

Plain oral capsules are the worst option for TB-500, and the published peptide bioavailability literature is clear on why. Stomach acid breaks down the peptide before it gets to the intestine, intestinal peptidase enzymes finish the job, and the liver clears most of whatever survives.

In practice, you would need many multiples of the injection dose to approximate the same systemic exposure, and even then the absorption would be too variable to predict. This is one of the reasons most oral peptide protocols underperform without a delivery technology designed to sidestep the gut.

Route comparison:

Route	Typical Per-Dose Range	Relative Bioavailability	Notes
Subcutaneous injection	2 to 5 mg	High (reference standard)	Requires reconstitution + syringe
Sublingual (validated, e.g. VERISORB)	2 to 5 mg	High (comparable to injection)	No needles; no reconstitution
Standard oral capsule	Not recommended	Low and variable	Most peptide is degraded in the gut

What does a typical TB-500 dosing cycle look like?

TB-500 is almost always run in defined cycles, not as a continuous protocol. The rationale is straightforward: the peptide's mechanism is repair-focused, so researchers structure a "loading" window to observe a response, then taper or stop.

In our protocol design work at Peak Human Labs, the pattern we see most often in reported research observations is a 4 to 6 week loading window producing the clearest signal. Users report subjective changes clustering in the second half of that window, which lines up with the satellite-cell migration timing the animal models describe. That is exactly what it is: a community-level observation, not a clinical result.

A typical TB-500 cycle: loading doses twice weekly, then optional maintenance once weekly, followed by a break.

Standard cycle structure:

Phase	Duration	Schedule	Weekly Dose
Loading	4 to 6 weeks	Twice weekly, 3 to 4 days apart	5 to 10 mg
Maintenance	4 to 6 weeks (optional)	Once weekly	2 to 5 mg
Off-cycle	4+ weeks	Nothing	None

A few timing notes that show up consistently in the research literature:

• Two-dose split. A typical week is Monday + Thursday or Tuesday + Friday, anything that puts roughly three to four days between doses.
• Loading then maintenance. Some researchers run only the loading phase, then go straight to an off-cycle. Others taper into a maintenance window first.
• No continuous use. Indefinite TB-500 administration is not how the animal data was structured and not how most research protocols are run.

Members experience this as a research window, not an ongoing supplement. The loading-then-off rhythm gives you a clean before-and-after comparison without the confound of continuous exposure.

How do you titrate TB-500 if you're new to it?

Most guides open straight at the standard 2 to 5 mg per dose with no ramp-up. For researchers new to TB-500, a graduated start gives you a cleaner baseline and a clearer view of any early response.

Titration also gives you a chance to detect any individual sensitivity before you commit to a full loading dose. There is no published data on injection-site reaction rates for TB-500 specifically, but the broader peptide research community recommends starting at the lower end as standard practice.

A three-week titration schedule showing how TB-500 dose increases gradually from 2mg to 5mg.

Week	Dose	Schedule	Rationale
1	2 mg	Twice weekly	Baseline; observe initial response
2	2.5 to 3 mg	Twice weekly	Incremental step
3+	2.5 to 5 mg	Twice weekly	Full loading dose if well tolerated

After loading, the maintenance phase typically drops back to a single weekly administration at 2 to 5 mg, then an off-cycle before any second loading window.

How do you reconstitute TB-500 for injection?

This section is for researchers using the subcutaneous injection route. If you're using a pre-formulated sublingual protocol like RESTORE, you can skip this entirely.

TB-500 for injection ships as a lyophilised powder (freeze-dried into a solid cake) in a sealed glass vial. You add bacteriostatic water (water with a small amount of benzyl alcohol added as a preservative) to dissolve it.

Reconstituting TB-500 powder: inject water slowly down the vial wall, then swirl gently until clear.

Reconstitution steps:

1. Let the vial come to room temperature before opening. Cold reconstitution reduces peptide solubility.
2. Draw bacteriostatic water into a syringe at the volume that matches the concentration you want.
3. Inject the water slowly down the inside wall of the vial, not directly onto the powder cake.
4. Swirl gently to dissolve. Do not shake; agitation can degrade the peptide.
5. The solution should be fully clear. If it's cloudy or has visible particles, discard it.

Concentration reference (5 mg vial):

Water Added	Concentration	0.1 mL delivers	0.2 mL delivers
1 mL	5,000 mcg/mL (5 mg/mL)	500 mcg	1 mg
2 mL	2,500 mcg/mL (2.5 mg/mL)	250 mcg	500 mcg

For most TB-500 protocols, the 1 mL reconstitution is the practical choice because the per-dose volume on a standard insulin syringe stays manageable at clinical doses. To draw a 2 mg dose at 5 mg/mL, you're pulling 0.4 mL. Use a U-100 insulin syringe with 0.01 mL graduations for accuracy.

Storage after reconstitution: Refrigerate at 2 to 8°C. Use within 28 days. Never freeze reconstituted solution; freeze-thaw cycles degrade the peptide structure.

Does body weight change TB-500 dosing?

Mostly no, based on the published animal protocols and how researchers actually run TB-500 in practice.

The interspecies scaling step uses body surface area to translate from rats to humans, but once you're in the human range, almost all published protocols use flat dosing. An 80 kg researcher and a 65 kg researcher are typically on the same 2 to 5 mg per administration schedule.

The exception is at the extremes. Researchers above 100 kg sometimes scale toward the upper end of the standard range; researchers under 60 kg occasionally stay at the lower end. The published rodent data doesn't support fine-grained weight-titration in adults, so the convention is to use weight as a tiebreaker between the upper and lower ends of the standard range rather than as a continuous variable.

How does TB-500 dosing compare with BPC-157?

Two peptides that get grouped together constantly, and one of the most common questions in dosing research is whether they share dose ranges. They don't.

	TB-500	BPC-157
Standard dose (research range)	5 to 10 mg per week	250 to 500 mcg per day
Schedule	Twice weekly	Daily
Per-dose magnitude	Milligrams	Micrograms
Standard route in published data	Subcutaneous	Subcutaneous or sublingual

TB-500 requires larger doses twice weekly, while BPC-157 uses smaller daily doses.

TB-500 doses sit roughly 10 to 30 times larger than BPC-157 doses on a per-administration basis, but TB-500 is dosed twice weekly while BPC-157 is daily. The two peptides target overlapping repair processes through different mechanisms, which is why some researchers run them in parallel within a single cycle and others pick one based on the tissue type they're studying.

If you're working out which of the two fits your research interest, the BPC-157 dose guide covers the per-day BPC-157 ranges and the cycle structure in full detail. The BPC-157 vs TB-500 mechanism comparison covers why their pathways differ.

RESTORE: TB-500 dosing context via VERISORB sublingual delivery

Most TB-500 protocols on the market today are injection-only. That means sourcing bacteriostatic water, syringes, reconstituting at the right concentration, drawing the right volume, and rotating injection sites week after week. For research interest in the peptide's repair profile, that's a high logistical overhead.

VERO's RESTORE Protocol approaches the same tissue-repair research surface differently. It pairs BPC-157 with TB-500 in a sublingual format using VERISORB Quicksome technology, which research suggests achieves bioavailability comparable to subcutaneous injection.

VERO RESTORE sublingual tablet delivers TB-500 without needles or reconstitution.

Three practical consequences for TB-500 dose planning:

• No reconstitution maths. No vials, no bacteriostatic water, no insulin syringes.
• Dose-equivalent delivery. Because VERISORB sublingual bioavailability is comparable to subcutaneous, the per-dose number matches the injection range rather than the inflated oral range.
• Hold the dose under your tongue for 60 to 90 seconds in a fasted state for optimal mucosal absorption.

All VERO protocols are for research purposes only.

Frequently Asked Questions

What is the standard dosage for TB-500?

The most commonly cited research range is 5 to 10 mg per week, typically split into two subcutaneous administrations three or four days apart. That number is an extrapolation from rodent studies using FDA interspecies scaling guidance, not a validated clinical dose. No published human efficacy trial has established a TB-500 dose, and fragment-specific human pharmacokinetic data has not been reported.

How long should a TB-500 cycle last?

Most TB-500 research protocols structure administration as a 4 to 6 week loading window with twice-weekly subcutaneous injections, followed by an optional reduced-frequency maintenance period and a planned off-cycle of at least 4 weeks. The cycle structure reflects the repair-focused mechanism: researchers are observing a response to injury signalling rather than maintaining continuous peptide levels. The specific duration varies across protocols and is not derived from a controlled human trial.

How often should TB-500 be administered?

Twice weekly is the conventional schedule during a loading phase, with doses spaced three to four days apart (for example Monday and Thursday). During an optional maintenance phase, once-weekly administration is standard. This rhythm comes from how researchers have applied TB-500 in extrapolated protocols, not from a published human pharmacokinetic schedule for the fragment specifically.

Is the TB-500 dose the same for sublingual and injection?

When the sublingual delivery system has been specifically validated for peptide bioavailability (such as VERISORB Quicksome), research suggests the sublingual dose can match the injection dose at 2 to 5 mg per administration. Generic sublingual sprays or compounded preparations without validated peptide bioavailability data do not have that equivalence. Standard oral capsules are not a recommended route for TB-500 because of degradation in the digestive tract.

Is TB-500 safe at these doses?

The only published human safety data covers intravenous full-length Thymosin Beta-4, not the TB-500 fragment, at doses from 42 mg to 1,260 mg in healthy volunteers. That 2010 study by Ruff et al. found no dose-limiting toxicity and dose-proportional pharmacokinetics across the escalation range, which is a meaningful safety signal for the parent molecule. Fragment-specific human safety data for TB-500 at typical research doses has not been published. All TB-500 use is conducted for research purposes only.

Should you titrate the TB-500 dose when starting?

A graduated start (2 mg in week one, 2.5 to 3 mg in week two, full 2.5 to 5 mg from week three onward) gives you a cleaner baseline observation and a chance to detect any individual sensitivity before committing to a full loading dose. This isn't required by any published protocol, but it is consistent with how researchers approach new peptides in general and reduces the noise in any early response.

Does body weight affect TB-500 dosing?

Mostly no, based on published animal protocols. Most TB-500 research uses flat dosing rather than weight-adjusted amounts; researchers above 100 kg sometimes scale toward the upper end of the standard range, and researchers under 60 kg sometimes stay at the lower end, but per-kilogram adjustment is not the convention. The weight-based scaling factor is used to derive the human range from rodent studies, not to fine-tune individual doses.

Key Takeaways

• No FDA-approved human TB-500 dose exists. The 5 to 10 mg per week range is an extrapolation from rodent data using FDA body-surface-area interspecies scaling, not a validated clinical figure.
• Route of administration is the single biggest variable. Subcutaneous injection and validated sublingual delivery (such as VERISORB Quicksome) can achieve comparable systemic exposure; standard oral capsules are not a recommended route because of digestive degradation.
• Twice-weekly subcutaneous administration is the standard schedule during a loading phase, with doses three to four days apart. Once-weekly is typical for the optional maintenance phase.
• Cycle structure matters: 4 to 6 weeks of loading, then optional maintenance, then a 4+ week off-cycle. Continuous TB-500 administration is not how the research has been structured.
• Titrate from a lower starting dose (2 mg in week one) for a cleaner baseline observation if you're new to TB-500. Full loading dose comes online from week three.
• For injectable protocols, standard reconstitution is 1 mL bacteriostatic water into a 5 mg vial (5 mg/mL). Store at 2 to 8°C; use within 28 days; never freeze.
• Body weight does not meaningfully change the per-dose figure within the human range. Flat dosing is the convention.

References

• Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences. 2010. https://pubmed.ncbi.nlm.nih.gov/20536472/. Retrieved 2026-06-03.
• Tokura Y, Nakayama Y, Fukada S et al. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. Journal of Biochemistry. 2011. https://pubmed.ncbi.nlm.nih.gov/20880960/. Retrieved 2026-06-03.
• Malinda KM, Sidhu GS, Mani H et al. Thymosin beta-4 in wound repair: animal-model evidence. Journal of Investigative Dermatology. 1999. https://pubmed.ncbi.nlm.nih.gov/10469335/. Retrieved 2026-06-03.
• Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4 as a multifunctional regenerative peptide: basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/. Retrieved 2026-06-03.
• Philp D, Kleinman HK. Animal studies of the tissue-repair and regeneration profile of thymosin beta. Annals of the New York Academy of Sciences. 2010. https://pubmed.ncbi.nlm.nih.gov/20536453/. Retrieved 2026-06-03.
• Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta-4 identified in TB-500. Drug Testing and Analysis. 2012. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/dta.1402. Retrieved 2026-06-03.
• U.S. National Library of Medicine. A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing. ClinicalTrials.gov NCT00311766. https://clinicaltrials.gov/study/NCT00311766. Retrieved 2026-06-03.
• U.S. FDA, Center for Drug Evaluation and Research. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. July 2005. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers. Retrieved 2026-06-03.

---

Researching a structured TB-500 protocol without reconstitution or injection logistics? Explore RESTORE →